Flavonoids from sideritis species: Human monoamine oxidase (hMAO) inhibitory activities, molecular docking studies and crystal structure of xanthomicrol

Molecules

Volumn 20, Issue 5, 2015, Pages 7454-7473

  Turkmenoglu, Fatma Pinar ^a   Baysal, Ipek ^a   Ciftci Yabanoglu, Samiye ^a   Yelekci, Kemal ^b   Temel, Hamdi ^c   Paşa, Salih ^c   Ezer, Nurten ^a   Çaliş, Ihsan ^d   Ucar, Gulberk ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b KADIR HAS UNIVERSITY   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

^d NEAR EAST UNIVERSITY   (Turkey)

Author keywords

Flavonoid; Inhibition; Molecular docking; Monoamine oxidase; Salvigenin; Sideritis; X ray diffraction investigation; Xanthomicrol

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); FLAVONE DERIVATIVE; ISOENZYME; MONOAMINE OXIDASE A, HUMAN; MONOAMINE OXIDASE INHIBITOR; PLANT MEDICINAL PRODUCT; SALVIGENIN; XANTHOMICROL;

CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR DOCKING; SIDERITIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; FLAVONES; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PLANT PREPARATIONS; SIDERITIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84929223384     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20057454     Document Type: Article

References (52)

1. Obon de Castro, C.; Rivera-Nunez, D. Phanerogamarum Monographiae Tomus XXI: A Taxonomic Revision of the Section Sideritis (genus Sideritis) (Labiatae); J. Cramer: Berlin, Germany, 1994.
2. Ezer, N.; Akcoş, Y. Flavonoids from Sideritis lycia. J. Hacettepe Univ. Fac. Pharm. 1995, 15, 81-87.
3. Knörle, R. Extracts of Sideritis scardica as triple monoamine reuptake inhibitors. J. Neural Transm. 2012, 119, 1477-1482.
4. Gonzalez-Burgos, E.; Carretero, M.E.; Gomez-Serranillos, M.P. Sideritis spp.: Uses, chemical composition and pharmacological activities-a review. J. Ethnopharmacol. 1996, 135, 209-225.
5. Barberan, F.A.T.; Tomas, F.; Ferreres, F. Isoscutellarein-7-0-allosyl (1-2) glucoside from Sideritis leucantha. J. Nat. Prod. 1985, 48, 28-32.
6. Küpeli, E.; Şahin, F.P.; Yeşilada, E.; Çaliş, ̄.; Ezer, N. In vivo anti-inflammatory and antinociceptive activity evaluation of phenolic compounds from Sideritis stricta. Z. Naturforschung 2007, 62c, 519-525.
7. Baytop, T. Daʇçayi. In Therapy with Medicinal plants in Turkey (Past and Present); Nobel Tip Publications: Istanbul, Turkey, 1999; p. 193.
8. Ezer, N.; Vila, R.; Canigueral, S.; Adzet, T. Essential oil composition of four Turkish species of Sideritis. Phytochemistry 1996, 41, 203-205.
9. Baser, K.H.C. Aromatic biodiversity among the flowering plant taxa of Turkey. Pure Appl. Chem. 2002, 74, 527-545.
10. Topçu, G.; Gören, A.C.; Kiliç, T.; Yildiz, Y.K.; Tümen, G. Diterpenes from Sideritis trojana. Nat. Prod. Lett. 2002, 16, 33-37.
11. Sahin, F.P.; Ezer, N.; Çališ, ̄. Three acylated flavone glycosides from Sideritis ozturkii Aytac &Aksoy. Phytochemistry 2004, 65, 2095-2099.
12. Sahin, F.P.; Ezer, N.; Çališ, ̄. Erratum to "three acylated flavone glycosides from Sideritis ozturkii Aytac and Aksoy" [Phytochemistry 65 (2004) 2095-2099]. Phytochemistry 2005, 66, 125.
13. Sahin, F.P.; Ezer, N.; Calis, I. Terpenic and phenolic compounds from Sideritis stricta. Turk. J. Chem. 2006, 30, 495-504.
14. Sezik, E.; Ezer, N. Phytochemical investigations on the plants used as folk medicine and herbal tea in Turkey I. Flavonoids of Sideritis congesta Davis et Huber-Morath. Acta Pharm. Turc. 1984, 16, 4-10.
15. Ezer, N.; Sakar, M.K.; Rodriguez, B.; de la Torre, M.C. Flavonoid glycosides and a phenylpropanoid glycoside from Sideritis perfoliata. Int. J. Pharmacogn. 1992, 30, 61-65.
16. Güvenc, A.; Okada, Y.; Akkol, E.K.; Uman, H.; Okuyama, T.; Calis, I. Investigations of anti-inflammatory, antinociceptive, antioxidant and aldose reductase inhibitory activities of phenolic compounds from Sideritis brevibracteata. Food Chem. 2010, 118, 686-692.
17. Tipton, K.F.; Boyce, S.; O'Sullivan, J.; Davey, G.P.; Healy, J. Monoamine oxidases: Certainties and uncertainties. Curr. Med. Chem. 2004, 11, 1965-1982.
18. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 1988, 25, 439-456.
19. Bach, A.W.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. USA 1988, 85, 4934-4938.
20. Johnston, J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 1968, 17, 1285-1297.
21. Knoll, J.; Magyar, K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 1972, 5, 393-408.
22. Pare, C.M. Unwanted effects of long-term medication in schizophrenia and depression. Pharmakop. Sych. Neuro. 1976, 9, 187-192.
23. Shih, J.; Chen, K.; Ridd, M.J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci. 1999, 22, 197-217.
24. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2002, 9, 22-26.
25. Binda, C.; Hubalek, F.; Li, M.; Edmondson, D.E.; Mattevi, A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett. 2004, 564, 225-228.
26. Edmondson, D.E.; Binda, C.; Mattevi, A. The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology 2004, 25, 63-72.
27. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. USA 2005, 102, 12684-12689.
28. Geldenhuys, W.J.; Darvesh, A.S.; Funk, M.O.; Van der Schyf, C.J.; Carroll, R.T. Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg. Med. Chem. Lett. 2010, 20, 5295-5298.
29. Jäger, A.K.; Saaby, L. Flavonoids and the CNS. Molecules 2011, 16, 1471-1485.
30. Carradori, S.; D'Ascenzio, M.; Chimenti, P.; Secci, D.; Bolasco, A. Selective MAO-B inhibitors: A lesson from natural products. Mol. Divers. 2014, 18, 219-243.
31. Mathew, B.; Suresh, J.; Mathew, G.E.; Parasuraman, R.; Abdulla, N. Plant secondary metabolites- potent inhibitors of monoamine oxidase isoforms. Cent. Nerv. Syst. Agents Med. Chem. 2014, 14, 28-33.
32. Gao, L.; Fang, J.S.; Bai, X.Y.; Zhou, D.; Wang, Y.T.; Liu, A.L.; Du, G.H. In silico target fishing for the potential targets and molecular mechanisms of baicalein as an anti-parkinsonian agent: Discovery of the protective effects on NMDA receptor-mediated neurotoxicity. Chem. Biol. Drug Des. 2013, 81, 675-687.
33. Küpeli, E.; Sahin, F.P.; Calis, I.; Yesilada, E.; Ezer, N. Phenolic compounds of Sideritis ozturkii and their in vivo anti-inflammatory and antinociceptive activities. J. Ethnopharmacol. 2007, 112, 356-360.
34. Tandogan, B.; Güvenç, A.; Çaliş, ̄.; Ulusu, N.N. In vitro effects of compounds isolated from Sideritis brevibracteata on bovine kidney cortex glutathione reductase. Acta Biochim. Pol. 2011, 58, 471-475.
35. Youdim, M.B.H.; Bakhle, Y.S. Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease. Br. J. Pharmacol. 2006, 147, S287-S296.
36. Finberg, J.P.M.; Gillman, K. Selective inhibitors of monoamine oxidase type B and the "cheese effect". In International Review of Neurobiology, Monoamine Oxidases and Their Inhibitors; Youdim, M.B.H., Riederer, P., Eds.; Academic Press: London, UK, 2011; Volume 100, pp. 169-190.
37. Fowler, J.S.; Volkow, N.D.; Logan, J.; Wang, G.J.; MacGregor, R.R.; Schlyer, D.; Wolf, A.P.; Pappas, N.; Alexoff, D.; Shea, C.; et al. Slow recovery of human brain MAO B after L-deprenyl (seleginine) withdrawal. Synapse 1994, 18, 86-93.
38. Lang, U.E.; Borgwardt, S. Molecular mechanisms of depression: Per-spectives on new treatment strategies. Cell Physiol. Biochem. 2013, 31, 761-777.
39. Meyer, J.H.; Ginovart, N.; Boovariwala, A.; Sagrati, S.; Hussey, D.; Garcia, A.; Young, T.; Young, N.T.; Praschak-Rieder, N.; Wilson, A.A.; et al. Elevated monoamine oxidase A levels in the brain: An explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006, 63, 1209-1216.
40. Gong, J.; Huang, J.; Ge, Q.; Chen, F.; Zhang, Y. Advanced research on the antidepressant effect of flavonoids. Curr. Opin. Complement. Altern. Med. 2014, 1, e00011.
41. Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A 2008, 64, 112-122.
42. Zheng, J.; Kwak, K.; Chen, X.; Asbury, J.B.; Fayer, M.D. Watching Ultrafast Molecular Motions with 2D IR Chemical Exchange Spectroscopy; World Scientific Publishing: London, UK, 2005.
43. Kanko, C.; Koukoua, G.; N'Guessan, Y.T.; Fournier, J.; Pradère, J.P.; Toupet, L. Contribution àl'étude phytochimique de Lippiamultiflora (Verbenaceae). C. R. Chim. 2004, 7, 1029-1032.
44. Ouyang, X.; Wei, L.; Pan, Y.; Huang, S.; Wang, H.; Begonia, G.B.; Ekunwe, S.I.N. Antioxidant properties and chemical constituents of ethanolic extract and its fractions of Ocimum gratissimum. Med. Chem. Res. 2013, 22, 1124-1130.
45. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Alcaro, S.; Ortuso, F.; Yáñez, M. Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl) hydrazones. J. Med. Chem. 2008, 51, 4874-4880.
46. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun. 2006, 344, 688-695.
47. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Chem. 1976, 72, 248-254.
48. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A.; Yáñez, M.; Orallo, F. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di (hetero) aryl-4,5-dihydro-(1-H)-pyrazole derivatives. Eur. J. Med. Chem. 2010, 45, 800-804.
49. Biological Macromolecular Resource. Available online: http://www.rcsb.org/pdb/home/ (accessed on 12 January 2015).
50. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 16, 2785-2791.
51. Yelekçi, K.; Büyüktürk, B.; Kayrak, N. In silico identification of novel and selective monoamine oxidase B inhibitors. J. Neural. Transm. 2013, 120, 853-858.
52. Gökhan-Kelekçi, N.; Şimşek, Ö.Ö.; Ercan, A.; Yelekçi, K.; Şahin, Z.S.; Işik, Ş.; Uçar, G.; Bilgin, A.A. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Bioorg. Med. Chem. 2009, 17, 6761-6772.